Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery

Shen, Haifa; Rodríguez-Aguayo, Cristian; Xu, Rong; González-Villasana, Vianey; Mai, Junhua; Huang, Yi; Zhang, Guodong; Guo, Xiaojing; Bai, Lina; Qin, Guoting; Deng, Xiaoyong; Li, Qingpo; Erm, Donald R.; Aslan, Burcu; Liu, Xuewu; Sakamoto, Jason; Chávez‐Reyes, Arturo; Han, Hee Dong; Sood, Anil K.; Ferrari, Mauro; López-Berestein, Gabriel

doi:10.1158/1078-0432.ccr-12-2764

Cited by 101 publications

(69 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have applied MSVs to effectively deliver small interfering RNA (siRNA) and microRNA into primary and metastatic tumors and demonstrated potent inhibition of gene expression and subsequent inhibition of tumor growth. [46][47][48] We recently identified a thioaptamer that binds specifically to E-selectin (ESTA) with a high affinity and conjugated ESTA onto the surface of a MSV to generate a delivery system that specifically targets the inflamed vasculature. 49 The feasibility of this ESTA-MSV delivery system has been successfully tested in mouse xenograft models of metastatic breast cancer and leukemia and has demonstrated drug enrichment in the disease lesions.…”

Section: Nanotechnology In Targeted Drug Deliverymentioning

confidence: 99%

Targeted Delivery of Shear Stress-Inducible microRNAs by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions

Wong¹,

Ma²,

Tian³

et al. 2016

Methodist DeBakey Cardiovascular Journal

Self Cite

View full text Add to dashboard Cite

Section: Nanotechnology In Targeted Drug Deliverymentioning

confidence: 99%

Targeted Delivery of Shear Stress-Inducible microRNAs by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions

Wong¹,

Ma²,

Tian³

et al. 2016

Methodist DeBakey Cardiovascular Journal

Self Cite

View full text Add to dashboard Cite

“…Several studies from MD Anderson Cancer Center have focused on the tyrosine kinase ephrin receptor EphA2, 158,159 which is observed to be highly expressed in ovarian cancer and associated with increased angiogenesis and metastatic invasion. 160–162 Nanoparticle-mediated siRNA delivery to knock down EphA2 expression showed significant reduction in in vivo tumor burden in mice ovarian cancer xenografts.…”

Section: Nanotechnology In Therapeuticsmentioning

confidence: 99%

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics

2014

View full text Add to dashboard Cite

Ovarian cancer is the deadliest of all gynecological cancers and the fifth leading cause of death due to cancer in women. This is largely due to late-stage diagnosis, poor prognosis related to advanced-stage disease, and the high recurrence rate associated with development of chemoresistance. Survival statistics have not improved significantly over the last three decades, highlighting the fact that improved therapeutic strategies and early detection require substantial improvements. Here, we review and highlight nanotechnology-based approaches that seek to address this need. The success of Doxil, a PEGylated liposomal nanoencapsulation of doxorubicin, which was approved by the FDA for use on recurrent ovarian cancer, has paved the way for the current wave of nanoparticle formulations in drug discovery and clinical trials. We discuss and summarize new nanoformulations that are currently moving into clinical trials and highlight novel nanotherapeutic strategies that have shown promising results in preclinical in vivo studies. Further, the potential for nanomaterials in diagnostic imaging techniques and the ability to leverage nanotechnology for early detection of ovarian cancer are also discussed.

show abstract

“…Since the first report revealing porous silicon particles-induced enhancement of paracellular delivery of insulin [25], sufficient advancement in developing pSi-based effective drug delivery systems for various kinds of therapeutic agents (e.g., pharmaceutical drugs (indomethacin (IMC) [26,27], doxorubicin (DOX) [28][29][30][31][32], paclitaxel [33], mitoxantrone dihydrochloride (MTX) [34,35], camptothecin (CPT) [36][37][38][39], and emodin [40]), therapeutic proteins (insulin [25,41], bovine serum albumin (BSA) [41], peptide [26,[42][43][44][45][46] ), and genes (siRNA [33,[47][48][49][50]), etc.) has been achieved in recent decades.…”

Section: Drug Deliverymentioning

confidence: 99%

“…For efficient [33]. Significantly, MSV/EphA2 in combination with paclitaxel (or docetaxel) led to great inhibition of tumor in the model mice.…”

Section: Protein and Gene Deliverymentioning

confidence: 99%

Silicon-Based Nanoagents for Cancer Therapy

2014

SpringerBriefs in Molecular Science

View full text Add to dashboard Cite

Nanotechnology has emerged as highly promising tools for cancer therapy. In comparison to traditional therapeutic methods (e.g., chemotherapy and radiotherapy) generally involving limited specificity and undesired side effects, nanomaterials (e.g., magnetic nanoparticles, carbon-based nanomaterials, and porous silicon, etc.)-based nanoagents and therapeutic strategies significantly facilitate the improvement of therapeutic efficacy and reduce the toxic side effect. In particular, silicon nanomaterials featuring large surface-to-volume ratio and abundant surface chemistry open up completely new avenues for design of novel silicon-based nanoagents with large drug-loading capacity and high tumor-targeting efficacy. In the past decade, porous silicon (pSi) has been widely employed as high-performance delivery systems for different types of therapeutic drug molecules, proteins, and genes, aiming at improved therapeutic efficacy and reduced toxic side effect. The pSi can be also functionalized with photosensitizers, radiosensitizers, or heat producers, which are efficacious for phototherapy or radiotherapy of cancer. On the other hand, silicon nanowires (SiNWs) and SiNWsbased nanohybrids (e.g., gold nanoparticles/nanospheres-coated SiNWs), serving as novel classes of drug nanocarriers and hyperthermia nanoagents, have recently been explored for in vitro and in vivo cancer therapy with encouraging therapeutic outcomes.

show abstract

Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery

Cited by 101 publications

References 24 publications

Targeted Delivery of Shear Stress-Inducible microRNAs by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions

Targeted Delivery of Shear Stress-Inducible microRNAs by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics

Silicon-Based Nanoagents for Cancer Therapy

Contact Info

Product

Resources

About